Favourable melanoma prognosis associated with the expression of the tumour necrosis factor receptor and the α1β1 integrin: A preliminary report

Melanoma Research

Volumn 7, Issue 6, 1997, Pages 486-495

  Gilhar, A ^a   Ullmann, Y ^b   Kalish, R S ^c   Berkutski, T ^d   Azizi, E ^d   Bank, I ^e  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b STONY BROOK UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Department of Dermatology ^*  (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

1 1 integrin; HLA DR; ICAM 1; IFN ; MeWo melanoma cells; Sk Mel 28; TNF

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; HLA DR ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT ALPHA INTERFERON A; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRALESIONAL DRUG ADMINISTRATION; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; INTEGRIN ALPHA1BETA1; INTEGRINS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031404306     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199712000-00007     Document Type: Article

References (35)

1. Guerr D, Schlichter LM. Disseminated melanoma - is there a new standard therapy? N Engl J Med 1992; 327: 560-561.
2. Runger TM, Klein CE, Decker JC, Brocker EB. The role of genetic instability, adhesion cell motility, and immune escape mechanisms in melanoma progression. Curr Opin Oncol 1994; 6: 188-196.
3. Kawano M, Hirano T, Matsuda P, Taga T, Hurii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanale H, Kuramoto A, Kishimoto T. Autocrine generation and general requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83-85.
4. Mule JJ, Güster MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immimol 1992; 148: 2622-2629.
5. Giavazzi R, Garofalo A, Banti MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, Dejana E. Interleukin-l induced augmentation of experimental métastases from a human melanoma in nude mice. Cancer Res 1990; 50: 4771-4775-
6. Castelli MP, Black PL, Schneider M, Pennington R, Abe F, Talmadge JE. Protective, restorative and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140: 3830-3833.
7. Mortarini R, Belli F, Parmiani G, Anichine A. Cytokine mediated modulation of HLA Class II, ICAM-1, LFA-3 and tumor associated antigen profile of melanoma cells. Comparison with anti proliferative activity by rIL-1-beta, rTNF-alpha, rIFN-gamma, rIL-4 and their combination. IntJ Cancer 1990; 45: 334-341.
8. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993; 100: 239S-244S.
9. Zouboulis CG, Schröder K, Garbe C, Krasagakis K, Kruger S, Orfanos CE. Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. J Invest Dermatol 1990; 96: 223S-230S.
10. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki, BM. Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocyte tumors. J Pathol 1993; 170: 429-434.
11. Gilhar A, Pillar T, David M, Eidelman S. Melanocytes and Langerhans cells in aged versus young skin before and after transplantation onto nude mice. J Invest Dermatol 1990; 96: 210- 214.
12. Kim JD, Lee JL, Park JH, Lee JM, Kim YH, Kim SJ. Induction of ICAM-1 and HLA-DR expression by IFNgamma in malignant melanoma cell lines. Yonsel Med 1995; 36: 15-25.
13. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, Maio M. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complementmediated cytotoxicity. IntJ Cancer 1995; 61: 5488-5556.
14. Bank I, Hemler M, Brenner MB, Cohen D, Levy V, Belko J, Grouse C, Chess L. A novel monoclonal antibody, 1B3.1, binds to a new epitope of the VLA-1 molecule. Cell Immunol 1989; 122: 416- 423.
15. Goodman MM, McCullough JL, Biren CA, Bar RJ. A model of human melanoma in cyclosporine-immunosuppressed rats. J Invest Dermatol 1987; 88: HI144.
16. Gilhar A, Ish-Shalom S, Pillar T, Etzioni A, Silbermann M. Effect of anti IGF-1 on epidermal proliferation of human skin transplanted onto nude mice treated with growth hormone. Endocrinology 1994; 134: 229-232.
17. Gilhar A, Pillar T, Etzioni A. Possible role of cytokines in cellular proliferation of the skin transplanted onto nude mice. Arch Dermatol 1995; 131: 38-42.
18. Decker JC, Schwinn A, Dummer R, Burg G, Brocker EB. Lesion-specific activation of cloned human tumorinfiltrating lymphocytes by autologous tumor cells: induction of proliferation and cytokine production. J Invest Dermatol 1993; 101: 15-21.
19. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. Human CD4+ cells specifically recognize a shared melanoma- associated antigen encoded by the tyrosinase gene. Proc NatlAcadSci USA 1994; 91: 9461-9465.
20. Scholer HR, Hatzopoulos AK, Balling R, Suzuki N, Grass P. A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor. EMBOJ 1989; 8: 2543-2550.
21. Corti A, Poiesi C, Merli S, Cassani G. Tumor necrosis factor (TNF alpha quantification by ELJSA and bioassay: effects of TNF-alpha-soluble TNF receptor (p55) complex dissociation during assay incubations. J Immunol Methods 1994; 177: 191-198.
22. Lejeune FJ, Lienard D, Levyrad S, Mirimanoff RO. Regional therapy of melanoma. Etir J Cancer 1993; 29A: 606-612.
23. Griffiths GEM, Barker JNWN, Kunkel S, Nickoloff BJ. Modulation of leukocyte adhesion molecules, a T cell chemotaxis and a regulator}' cytokine in allergic contact dermatitis (rhus dermatitis). Br J Dermatol 1991; 124: 519-526.
24. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas A, Taverier J, Fiers W. Human tumor xenografts treated with recombinant tumor necrosis factor alone or in combination with interferon. Cancer Res 1986; 46: 3990-3993.
25. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-1455.
26. Ernstoff MS, Fusi S, Kirkwood JM. Parameters of interferon action: I. Immunological effects of whole cell leukocyte (IFN-alpha) in phase HI trial. J Diol Response Mod 1983; 6: 528-539.
27. Ernstoff MS, Fusi S, Kirkwood JM. Parameters of interferon action. II. Immunological effects of recombinant leukocyte interaction (IFN-alpha) in phase MI trial. J Biol Response Mod 1983; 6: 540-547.
28. Garbe C, Kreuser ED, Zoubolis CG, Stadier R, Orfanos CE. Combined treatment of metastatic melanoma with intereron and cytotoxic drugs. Sem Oncol 1992; 19(4): 63-69.
29. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991; 10: 115-128.
30. Kramer RH, Mai V, Cheng YG, Ramos DM. Integrin expression in malignant melanoma. Cancer Metastasis Rev 1991; 10: 49-59.
31. Bank I, Book M, Ware R. Functional role of VLA-1 (CD49a) in adhesion, cation dependent spreading, and activation of cultured human T lymphocytes. Cell Imimmol 1994; 156: 424-437.
32. Kern A, Briesewitz R, Bank I, Marcantonio EE. The role of the I domain in ligand binding of the human integrin a^i.JBiol Cbein 1994; 269: 22811-22816.
33. Klein CE, Steinmayer T, Kaufman F, Weber L, Brocker E-B. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Derinatol 1991; 96: 281-284.
34. Anichini A, Mortarini R, Supino R, Parmiani G. Human melanoma cells with high susceptibility to cellmediated lysis can be identified on the basis of ICAM-1 phenotype, VIA profile and invasive ability. Int J Cancer 1990; 46: 508-515.
35. Ruoslaht E, Reed J . Anchorage dependence, integrins, and apoptosis. Cell 1994; 77: 477-478.